Clinical Trials in Los Angeles

Showing 3801-3820 of 16,901 trials

A Study of LM-24C5 For Advanced Solid Tumors

NCT06187402

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

Advanced Solid Tumor

LaNova Medicines Limited49 participantsStarted Dec 2023

Los Angeles, California, United States • Ocala, Florida, United States • Indianapolis, Indiana, United States +3 more locations

RECRUITINGPhase 1< 1 mile

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.

Advanced CancerBreast CancerAdvanced Solid Tumors+1 more

OnKure, Inc.200 participantsStarted Feb 2024

Encinitas, California, United States • La Jolla, California, United States • Los Angeles, California, United States +31 more locations

A Study of LM-24C5 For Advanced Solid Tumors

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Find Trials by Condition in Los Angeles

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

International Rare Brain Tumor Registry

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

CREST-2 Long-term Observational Extension Study

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

FebriDx® Method Comparison Study Protocol

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Phase 2b Study of ALTO-100 in MDD

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Skin Reactions Related to Thoracic Implantable Chamber Dressings